Hubbry Logo
PanniculitisPanniculitisMain
Open search
Panniculitis
Community hub
Panniculitis
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Panniculitis
Panniculitis
Panniculitis
View on Wikipedia
from Wikipedia
Panniculitis
Erythema induratum, a form of lobular panniculitis
SpecialtyRheumatology Edit this on Wikidata

Panniculitis is a group of diseases whose hallmark is inflammation of subcutaneous adipose tissue (the fatty layer under the skin – panniculus adiposus).[1] Symptoms include tender skin nodules, and systemic signs such as weight loss and fatigue.

Restated, an inflammatory disorder primarily localized in the subcutaneous fat is termed a "panniculitis", a group of disorders that may be challenging both for the clinician and the dermatopathologist.[2]: 487  The general term for inflammation of any adipose tissue is steatitis.

Signs and symptoms

[edit]

Panniculitis can also be classified based on the presence or absence of systemic symptoms. Panniculitis without systemic disease can be a result of trauma or cold.[3] Panniculitis with systemic disease can be caused by[citation needed]:

This is not a complete list of possible causes.

Associated conditions

[edit]

Lipoatrophy or lipodystrophy (the loss of subcutaneous adipose tissue) can occur in any of these conditions.[citation needed]

Diagnosis

[edit]

Classification

[edit]

It can occur in any fatty tissue (cutaneous or visceral) and is often diagnosed based on a deep skin biopsy, and can be further classified by histological characteristics based on the location of the inflammatory cells (within fatty lobules or in the septa which separate them) and on the presence or absence of vasculitis.[citation needed]

There are thus four main histological subtypes:[4]

  1. lobular panniculitis without vasculitis (acute panniculitis, previously termed Weber–Christian disease,[5] systemic nodular panniculitis)
  2. lobular panniculitis with vasculitis
  3. septal panniculitis without vasculitis
  4. septal panniculitis with vasculitis

Lobular

[edit]
With vasculitis
[edit]

Erythema induratum, or "Bazin disease", is a panniculitis on the back of the calves.[6] It was formerly thought to be a reaction to the tuberculum bacillus. It is now considered a panniculitis that is not associated with a single defined pathogen.[7]

Nodular vasculitis is a skin condition characterized by small, tender, reddened nodules on the legs, mostly on the calves and shins. Microscopically, there are epithelioid granulomas and vasculitis in the subcutaneous tissue, making it a form of panniculitis. Most of these cases are now thought to be manifestations of tuberculosis, and indeed they respond well to anti-tuberculous treatment.[citation needed]

Without vasculitis
[edit]

Non-vasculitis forms of panniculitis that may occur include:

  • Cytophagic histiocytic panniculitis was first described in 1980 by Winkelmann as a chronic histiocytic disease of the subcutaneous adipose tissue, which is characterized clinically by tender erythematous nodules, recurrent high fever, malaise, jaundice, organomegaly, serosal effusions, pancytopenia, hepatic dysfunction and coagulation abnormalities.[2]: 494 [8] CHP may occur either isolated or as part of cutaneous manifestations of hemophagocytic syndrome (HPS).[9] CHP is a rare and often fatal form of panniculitis with multisystem involvement. But it can also present in a benign form involving only the subcutaneous tissue, thus having a broad clinical spectrum.
  • Traumatic panniculitis is a panniculitis that occurs following trauma to the skin.[2]: 492 [10]
  • Cold panniculitis is a panniculitis occurring after exposure to cold, most often seen in infants and young children.[2]: 491  This condition has been described in children who suck ice or popsicles, and therefore is sometimes referred to as "popsicle panniculitis."[2]: 491 [10] The term was coined when a patient with a rash of unknown origin on her cheek was taken to a dermatologist.[11]
  • Gouty panniculitis is a panniculitis caused by deposition of uric acid crystals in gout.[2]: 494 
  • Pancreatic panniculitis (also known as enzymatic panniculitis, Pancreatic fat necrosis,[10] and subcutaneous fat necrosis) is a panniculitis most commonly associated with pancreatic carcinoma, and more rarely with anatomic pancreatic abnormalities, pseudocysts, or drug-induced pancreatitis.[2]: 493 
  • Factitial panniculitis is a panniculitis that may be induced by the injection of organic materials, povidone, feces, saliva, vaginal fluid, and oils.[2]: 492 

With needle-shaped clefts

[edit]

Lipodermatosclerosis is a form of panniculitis associated with chronic venous insufficiency that presents with brown indurations on the front of the shins. It may be associated with pain and other signs of chronic venous insufficiency. The exact cause is unknown.[12]

Other forms include:

Septal

[edit]
Erythema nodosum
[edit]
Main article: Erythema nodosum

Erythema nodosum is a form of panniculitis characterised by tender red nodules, 1–10 cm, associated with systemic symptoms including fever, malaise, and joint pain. Nodules may become bluish-purple, yellowing, and green, and subside over 2–6 weeks without ulcerating or scarring. Erythema nodosum is associated with infections, including Hepatitis C, EBV and tuberculosis, Crohn's disease and sarcoidosis, pregnancy, medications including sulfonamides, and some cancers, including Non-Hodgkin lymphoma and pancreatic cancer.[15]

A1AT-deficiency-associated
[edit]
See also: Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency panniculitis[13] is a panniculitis associated with a deficiency of the α1-antitrypsin enzyme inhibitor.[2]: 494 

Treatment

[edit]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Panniculitis

View on Grokipedia
from Grokipedia
Panniculitis refers to a group of relatively uncommon inflammatory disorders affecting the subcutaneous , presenting as tender, erythematous nodules or plaques typically on the lower extremities. These conditions arise from various etiologies and are not merely extensions of dermal or fascial , distinguishing them as primary disorders of the hypodermis. Clinically, panniculitis manifests with painful subcutaneous lesions that may evolve into ulcers, , or sclerosis, often requiring histopathological confirmation for accurate diagnosis. The classification of panniculitis is primarily based on histopathological patterns, dividing it into septal and lobular forms, with further subdivision depending on the presence or absence of . Septal panniculitis involves inflammation primarily along the fibrous septa separating fat lobules, exemplified by (without vasculitis) or leukocytoclastic -associated cases. In contrast, lobular panniculitis targets the fat lobules themselves, including subtypes like subcutaneous fat necrosis of the newborn (without vasculitis) or of Bazin (with vasculitis). This lobular-septal dichotomy, combined with vascular involvement, guides differential diagnosis and highlights the heterogeneous nature of these disorders. Etiologically, panniculitis can stem from infections (such as ), trauma, enzymatic destruction (e.g., in ), autoimmune processes, malignancies, or metabolic disturbances like alpha-1-antitrypsin deficiency. Symptoms often include localized pain, fever, or systemic signs if an underlying condition is present, with lesions varying in size and distribution based on the subtype—such as calves in or thighs in cold-induced forms. Diagnosis typically involves a detailed clinical history, , and deep incisional (at least 6 mm) to assess inflammatory patterns, , and vascular changes. Management of panniculitis focuses on treating the underlying cause when identifiable, alongside supportive measures like nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids for symptom relief. In infectious cases, targeted antimicrobial therapy—such as prolonged antitubercular regimens—may be necessary, while autoimmune or idiopathic forms often respond to immunosuppressants or observation. Surgical intervention is reserved for complications like abscesses, emphasizing the role of an interprofessional approach for optimal outcomes in this rare spectrum of diseases.

Overview

Definition and Characteristics

Panniculitis encompasses a diverse group of inflammatory disorders primarily affecting the subcutaneous , also known as the , which is the deepest layer of the skin beneath the . This typically targets either the lobules—clusters of adipocytes—or the fibrous that divide them, leading to a classification into lobular, septal, or mixed forms. Unlike superficial conditions, panniculitis originates in the hypodermis and generally spares the overlying and , although secondary changes in these layers may occur in some cases. The condition is distinguished from other inflammatory dermatoses, such as those involving the (e.g., ) or (e.g., ), by its predominant localization to the subcutaneous compartment without representing an extension of deeper or more superficial processes. This anatomical specificity is crucial for histopathological evaluation, as panniculitis requires inflammation centered in the subcutaneous fat rather than incidental involvement amid primary dermal or . Clinically, panniculitis presents with tender, erythematous subcutaneous nodules or plaques that are often firm and ill-defined, most frequently appearing on the lower extremities such as or calves. These lesions typically evolve from an initial bright red hue to a bruised-like appearance with bluish or yellowish discoloration as the progresses, reflecting stages of hemorrhage and . In many instances, the nodules resolve spontaneously over a period of weeks to months, potentially leaving atrophic depressions, , or scarring, though recurrence is possible depending on the underlying process.

Epidemiology

Panniculitis is a rare inflammatory condition of the subcutaneous , with an estimated incidence of 1 to 5 cases per 100,000 individuals annually in the general population for its most common subtype, (EN), which drives the overall rate; rarer forms contribute to a total under 1 per 100,000. The disease exhibits a strong demographic skew, occurring more frequently in women with a female-to-male of approximately 3:1 to 5:1 across various forms, though this ratio approaches 1:1 in pediatric cases. Idiopathic variants, such as EN, typically peak in incidence between the ages of 20 and 40 years, while secondary forms associated with underlying conditions like infections or autoimmune diseases often manifest in older adults. Geographic and ethnic variations influence the occurrence of specific subtypes; EN is associated with autoinflammatory disorders like , which is prevalent in certain Mediterranean ethnic groups. Additionally, panniculitis subtypes such as demonstrate elevated associations in tuberculosis-endemic regions, including parts of and , where serves as a key trigger. Overall incidence trends have remained stable over decades, though cases of panniculitis have been reported as post-infectious sequelae following infections, documented from 2020 through 2025. Incidence varies regionally, with higher EN rates reported in (e.g., 12-14 per 100,000 in ).

Clinical Presentation

Signs and Symptoms

Panniculitis is characterized by the development of painful, tender subcutaneous nodules typically measuring 1 to 5 cm in diameter, which are often bilateral and located on , thighs, or arms. These nodules usually present with overlying warmth and at onset, reflecting the inflammatory process in the subcutaneous fat layer. In common septal forms like , the nodules evolve from an initial red appearance to purple, bruising-like discoloration within 1 to 2 weeks, before gradually resolving over 3 to 6 weeks, potentially leaving residual or cutaneous . Ulceration or suppuration occurs rarely in uncomplicated septal cases but can be more common in certain lobular subtypes. Systemic manifestations, including fever, malaise, and arthralgias, may accompany the skin findings, with frequency varying by subtype. Clinical presentation can vary, with superficial forms appearing more distinctly nodular and tender, whereas deeper variants exhibit less well-defined borders and may involve larger areas of induration. These features may signal associations with underlying systemic diseases, though the direct manifestations remain centered on the subcutaneous .

Associated Conditions

Panniculitis often manifests as a secondary condition linked to various systemic disorders, though the proportion of cases attributable to underlying illnesses varies by subtype; for example, in , approximately 50% have identifiable triggers. This association underscores the importance of evaluating patients for comorbidities, as panniculitis may serve as an initial cutaneous indicator of broader disease states. Secondary forms are particularly prevalent in subtypes like . Infectious etiologies represent a significant proportion of secondary panniculitis, especially . Streptococcal infections, particularly , are the most common bacterial trigger worldwide, affecting up to 22% of pediatric cases. Tuberculosis is another key association, with primary infection or cutaneous forms like linked to in endemic regions, though rare in low-prevalence areas. infections have also been implicated, often presenting with gastrointestinal symptoms alongside nodular lesions. More recently, post-viral panniculitis has been documented following , with cases of eosinophilic, generalized lymphocytic, and mesenteric variants reported since 2020. Autoimmune and rheumatic conditions frequently underlie panniculitis, with serving as a hallmark manifestation. is associated in 10-22% of cases, often correlating with a favorable and acute onset. , including and , triggers up to 15% of instances, while systemic is implicated in rarer cases, sometimes as an initial sign. Panniculitis has also been reported in , typically as tender nodules on the trunk and extremities. Approximately 50% of remains idiopathic, but in certain populations, such as those with , human (HLA)-B51 positivity is linked to increased susceptibility and more severe presentations involving . Other notable associations include , a leading to lobular panniculitis through unchecked protease activity, often presenting with painful, ulcerating nodules. Pancreatic disorders, such as or acinar cell carcinoma, cause neutrophilic panniculitis via lipase-mediated , with skin lesions appearing in up to 2-3% of cases and preceding malignancy diagnosis in some. Malignancies like subcutaneous panniculitis-like mimic inflammatory panniculitis histologically but represent a neoplastic process affecting less than 1% of non-Hodgkin lymphomas; the association between mesenteric panniculitis and malignancy remains debated as of 2025. Drug-induced forms, including those from used for , can produce nodosum-like reactions through mechanisms.

Etiology and Pathophysiology

Causes and Risk Factors

Panniculitis has a diverse encompassing infections, trauma, enzymatic destruction of fat, autoimmune processes, malignancies, and metabolic disorders. Infections, such as those caused by or other and fungi, can directly involve subcutaneous fat or trigger reactive . Enzymatic causes include pancreatic panniculitis from lipase release in , leading to fat . Autoimmune conditions like and factitial panniculitis, as well as malignancies such as , contribute through immune dysregulation or direct infiltration. Metabolic factors, notably alpha-1-antitrypsin deficiency, impair protease inhibition and promote fat . These processes often involve immune-mediated responses to various antigens within subcutaneous , manifesting as reactions in many cases. These reactions can be triggered by diverse stimuli, leading to of the lobules or , though the precise mechanisms vary by subtype. Several risk factors predispose individuals to panniculitis, including , which increases the vulnerability of expanded to inflammatory insults, particularly in cold-induced forms. Exposure to cold temperatures is a well-recognized trigger, as seen in panniculitis frigorigena, where of in subcutaneous occurs more readily in susceptible populations such as obese adults or infants with higher brown content. Trauma to the skin or underlying tissue can also initiate panniculitis by disrupting architecture and provoking localized immune responses. Hormonal influences, such as fluctuations in women, contribute to risk, with associations noted in conditions like during pregnancy or with oral contraceptive use. Genetic predispositions are rare but documented in familial forms of panniculitis, including autoinflammatory syndromes with panniculitis and familial clustering in subcutaneous panniculitis-like , often linked to in genes regulating immune responses. Environmental triggers encompass medications, such as rapid withdrawal of systemic corticosteroids, which can precipitate post-steroid panniculitis through rebound in . Certain vaccines, including mRNA formulations and measles vaccines, have been implicated in rare cases of panniculitis onset or exacerbation via mechanisms. Toxins and other external agents may similarly provoke episodes, though reports remain sporadic as of 2025.

Inflammatory Mechanisms

Panniculitis encompasses a spectrum of inflammatory processes in subcutaneous , with distinct pathogenic pathways differentiating septal and lobular involvement. In septal panniculitis, primarily targets the fibrous septa separating fat lobules, often initiated by damage to small venules or lymphatic structures, leading to localized and perivascular infiltration by lymphocytes and histiocytes. This pathway contrasts with lobular panniculitis, where direct injury causes of fat cells within the lobules, triggering a cascade of inflammatory cell recruitment and tissue breakdown. Proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), are central to amplifying these responses by promoting the and migration of neutrophils and lymphocytes to the inflamed sites. These mediators, released from activated adipocytes and resident immune cells, sustain the inflammatory milieu and contribute to and cellular infiltration across both septal and lobular patterns. Vasculitis contributes significantly to the inflammatory dynamics in many panniculitides, particularly those with septal predominance, where of postcapillary venules induces endothelial damage, fibrinoid necrosis, and subsequent ischemia of adjacent . This vascular involvement leads to fat lobule and exacerbates the panniculitic process, as seen in conditions like , where vascular alterations are evident in approximately 90% of cases. In crystal-induced variants, such as post-steroid panniculitis, needle-shaped clefts—representing dissolved crystals within adipocytes—provoke a granulomatous reaction, further driving local inflammation through activation. Chronic evolution of panniculitis involves resolution of acute infiltrates and progression to , characterized by deposition and septal thickening, alongside lipophagia where macrophages engulf and degrade necrotic debris, forming multinucleated giant cells and foam cells. In autoimmune-associated forms, such as lupus panniculitis, immune-mediated targeting of subcutaneous fat by autoantibodies and lymphoid infiltrates perpetuates this fibrotic remodeling.

Diagnosis

Clinical Evaluation

The clinical evaluation of panniculitis begins with a detailed history taking to identify potential etiologies and guide further assessment. Clinicians should inquire about the onset and progression of subcutaneous nodules, including acute versus chronic development, which can suggest infectious or inflammatory triggers. Triggers such as recent travel (potentially indicating infectious causes like ), medication use (e.g., drugs like associated with panniculitis), or trauma should be explored, as these may point to reactive forms. Systemic symptoms, including fever, arthralgias, , or gastrointestinal complaints, are assessed to detect underlying conditions like autoimmune diseases or malignancies. Additionally, family history is crucial for recognizing genetic forms, such as those linked to . Physical examination focuses on characterizing the lesions to inform the . is essential to evaluate nodule depth, distinguishing superficial subcutaneous involvement from deeper fascial extension, and to assess tenderness, which is common in inflammatory panniculitides. Lesion distribution patterns are noted, such as pretibial predominance in or bilateral lower extremity involvement in other idiopathic cases, aiding in without invasive procedures. The exam also checks for associated skin changes like , ulceration, or , and systemic signs such as . Initial laboratory tests provide supportive evidence of inflammation or systemic involvement. A complete blood count (CBC) may reveal eosinophilia suggestive of parasitic or hypersensitivity-related panniculitis, while elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) indicates active inflammation. Antinuclear antibody (ANA) testing screens for autoimmune associations, such as lupus panniculitis. Imaging, particularly , is useful for non-invasively assessing lesion depth, vascularity, and echogenicity to differentiate panniculitis from other subcutaneous pathologies; high-frequency can also help distinguish septal from lobular patterns. Differential diagnosis emphasizes clinical correlation to exclude mimics. Conditions like are ruled out by the absence of fever, , or rapid spread, often confirmed by lack of response to antibiotics. thrombosis (DVT) is considered in unilateral leg nodules and excluded via Doppler if vascular symptoms are present. Benign lipomas are differentiated by their nontender, mobile nature and lack of on exam. These distinctions rely on integrating , exam, and basic tests before considering more advanced evaluations.

Histopathological Findings

Diagnosis of panniculitis relies on histopathological examination of tissue obtained through biopsy, which is essential for confirming the involvement of the subcutaneous fat layer. The preferred biopsy methods include a deep incisional biopsy or a 6 mm punch biopsy, performed on the edge of an active lesion to capture representative subcutaneous tissue while avoiding areas of resolution or scarring that may yield nondiagnostic samples. The skin should be cleansed with alcohol prior to the procedure to minimize contamination, and any necrotic areas should be included for additional cultures if infection is suspected. Histologically, panniculitis is characterized by an inflammatory infiltrate primarily confined to the , distinguishing it from dermal inflammatory conditions. The is structured into lobules composed of adipocytes and septa containing , vessels, and nerves; on , adipocytes often appear empty or with signet-ring morphology due to dissolution during processing. This subcutis-specific without significant dermal involvement is a hallmark feature. Key histopathological patterns differentiate subtypes of panniculitis. In septal panniculitis, there is thickening of the fibrous septa with a predominantly lymphocytic infiltrate, as seen in conditions like where Miescher radial granulomas may form. In contrast, lobular panniculitis features of adipocytes within lobules, often accompanied by neutrophils and ghost-like cells, exemplified by pancreatic panniculitis with . Special stains and ancillary techniques enhance diagnostic accuracy. Polarized light microscopy can detect foreign materials such as crystals or parasites, while fungal and acid-fast bacilli stains identify infectious organisms. , including staining to highlight macrophages and histiocytes, is used for characterizing cellular infiltrates in granulomatous or atypical cases. Additionally, (PCR) assays are employed in atypical presentations to detect infectious agents, such as mycobacteria, or to assess T-cell clonality in suspected .

Classification

Septal Panniculitis

Septal panniculitis is characterized by primarily localized to the fibrous that separate subcutaneous lobules, which may be accompanied by involving small vessels within the septa. This pattern distinguishes it from other forms of panniculitis by the predominant involvement of septal structures, with relative sparing of the fat lobules in early stages. The most common subtype is , an acute, self-limited condition presenting as tender, erythematous nodules typically on the anterior shins of young adults, often triggered by infections, medications, or systemic diseases. Histologically, it features septal widening due to and a mixed inflammatory infiltrate of lymphocytes, histiocytes, and neutrophils around vessels, with characteristic Miescher radial granulomas in mature lesions. Another key subtype is scleroderma-related panniculitis, seen in localized forms such as profunda or systemic sclerosis, which manifests as chronic, indurated plaques on the trunk or extremities with progressive replacing . In these cases, reveals thickened septa with dense collagen bundles, perivascular lymphocytic infiltrates, and eventual hyalinization, correlating clinically with bound-down skin and reduced mobility. Subtypes with , such as nodular vasculitis, show leukocytoclastic changes in septal vessels. Diagnostic criteria for septal panniculitis rely on clinicopathologic , requiring a deep to confirm septal-centered with or without , excluding lobular . Within septal variants, differentiation from —associated with —is essential; the latter shows membrane-like , fat with pseudocysts, and vascular in addition to septal involvement, often in the context of lower leg and .

Lobular Panniculitis

Lobular panniculitis is characterized by primarily affecting the fat lobules of the , which may or may not involve or vascular changes. This pattern distinguishes it as a form of panniculitis where the inflammatory process is centered within the lobules, often leading to necrosis and subsequent inflammatory cell infiltration. Clinically, it manifests as tender, erythematous subcutaneous nodules or plaques, most commonly on the lower extremities, which may evolve to include ulceration or drainage in some cases. Key variants of lobular panniculitis include idiopathic forms and those associated with specific underlying conditions. Weber-Christian disease, also known as idiopathic lobular panniculitis, presents with recurrent episodes of fever accompanied by tender, nonsuppurative subcutaneous nodules, sometimes with systemic symptoms such as fatigue and . Histologically, it features a predominantly lobular infiltrate of lymphocytes, histiocytes, and neutrophils surrounding areas of . Another prominent variant is pancreatic panniculitis, which arises from pancreatic disorders like or pancreatic carcinoma, where released lipolytic enzymes such as cause enzymatic digestion of subcutaneous fat. This leads to tender, erythematous-to-violaceous nodules on the legs that may ulcerate and exude oily fluid; up to 49% of cases precede overt pancreatic symptoms. Clinical presentation often involves deeper-seated nodules that are less superficially tender compared to other inflammatory conditions, correlating with the lobular involvement. Histopathological examination reveals characteristic features such as ghost-like adipocytes (anucleated cells with shadowy outlines), needle-shaped clefts within necrotic fat cells from crystallized fatty acids, and a mixed inflammatory infiltrate including neutrophils and histiocytes, without vascular damage in many cases. These findings aid in distinguishing lobular panniculitis from other subcutaneous inflammatory processes. Subtypes with , such as of Bazin, demonstrate lobular inflammation with associated granulomatous . Rare forms of lobular panniculitis include factitial panniculitis, resulting from self-induced trauma or injection of foreign substances, which shows acute lobular inflammation with and a robust neutrophilic response on . Calciphylaxis-related panniculitis, often seen in patients with end-stage renal disease, involves lobular with ghost adipocytes and associated vascular , leading to painful, ischemic nodules prone to ulceration.

Management

Treatment Approaches

The management of panniculitis primarily focuses on alleviating symptoms, reducing , and addressing the underlying , with treatment strategies varying based on the specific subtype and severity. Supportive care forms the foundation of therapy for most cases, including rest and elevation of the affected limbs to minimize swelling and discomfort, particularly in lower extremity involvement. Compression therapy, such as , is recommended for lesions on the legs to improve lymphatic drainage and reduce . Nonsteroidal anti-inflammatory drugs (NSAIDs), like indomethacin at 50 mg three times daily, are commonly employed to control pain and in symptomatic patients. Specific anti-inflammatory therapies are indicated for more persistent or widespread disease. Corticosteroids remain a cornerstone, with topical formulations applied for mild, localized lesions to target superficial inflammation, while systemic corticosteroids, such as prednisone at 0.5-1 mg/kg daily, are used for severe or generalized cases to achieve rapid resolution. Immunosuppressive agents are reserved for refractory presentations; for instance, colchicine at 1-2 mg daily, adjusted for body weight, has demonstrated efficacy in erythema nodosum, a septal form of panniculitis, by inhibiting neutrophil chemotaxis and reducing lesion recurrence. Dapsone, at doses of 50-150 mg daily, is particularly effective for neutrophilic variants, such as those associated with alpha-1 antitrypsin deficiency, due to its antineutrophilic properties that promote remission and maintenance; for alpha-1 antitrypsin deficiency specifically, augmentation therapy with intravenous alpha-1 antitrypsin infusions may be considered as a cause-directed approach. Cause-directed interventions are essential when an identifiable trigger is present. Infectious panniculitides, such as those due to bacterial or mycobacterial causes, require targeted antibiotics, with selection guided by culture results to eradicate the and prevent progression, often leading to favorable outcomes with appropriate . In drug-induced cases, prompt discontinuation of the offending agent, such as oral contraceptives or certain medications, often leads to spontaneous resolution without further intervention. Recent advances have introduced biologic therapies for refractory panniculitis linked to autoimmune conditions, expanding options beyond traditional immunosuppressants. Anti-tumor necrosis factor (TNF) agents, including and , have shown promise in autoimmune-associated forms, such as those in or , with reported complete responses in cases unresponsive to corticosteroids, though monitoring for paradoxical reactions is advised. varies with , but early often improves outcomes.

Prognosis and Complications

The prognosis of panniculitis varies significantly depending on whether it is idiopathic or secondary to an underlying condition. In idiopathic cases, such as , the most common form, lesions typically resolve spontaneously within 3 to 8 weeks without scarring or long-term sequelae. For secondary panniculitis, outcomes are closely tied to the management of the primary ; for instance, infectious causes often achieve resolution with appropriate therapy, while autoimmune or malignant associations may persist or worsen without targeted intervention. Recurrence occurs in approximately one-sixth to one-third of idiopathic cases, with higher rates—up to 50%—observed in autoimmune-related forms due to ongoing inflammatory triggers. Factors such as and incomplete resolution of predisposing conditions can elevate recurrence risk, often manifesting as episodic flares over months to years. Complications are uncommon but can include resulting in oil cysts, post-inflammatory , or secondary bacterial infections, particularly in deeper lobular involvement. In malignancy-associated panniculitis, systemic dissemination may lead to multi-organ involvement, though this remains rare. Long-term monitoring is recommended for chronic or recurrent forms, involving annual clinical evaluations and screening for comorbidities like , with recent guidelines emphasizing multidisciplinary follow-up to detect progression early.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK606121/
  2. https://revistamedicinamilitara.ro/wp-content/uploads/2023/01/RJMM-vol-CXXVI-nr-4-din-2023-part-12.pdf
  3. https://www.uptodate.com/contents/panniculitis-recognition-and-diagnosis
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7938036/
  5. https://www.aafp.org/pubs/afp/issues/2007/0301/p695.html
  6. https://www.ncbi.nlm.nih.gov/books/NBK470369/
  7. https://www.rheumaknowledgy.com/panniculitis/
  8. https://gpnotebook.com/pages/dermatology/panniculitis
  9. https://medicaljournalssweden.se/actadv/article/download/8624/12105/40546
  10. https://www.dermpathdiagnostics.com/clinicians/panniculitis/
  11. https://advancesinrheumatology.biomedcentral.com/articles/10.1186/s42358-019-0077-5
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC11337221/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8723782/
  14. https://www.actasdermo.org/es-eosinophilic-panniculitis-associated-with-covid-19-articulo-S157821902030278X
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8884126/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9025345/
  17. https://plasticsurgerykey.com/panniculitis-8/
  18. https://www.merckmanuals.com/professional/dermatologic-disorders/hypersensitivity-and-reactive-skin-disorders/panniculitis
  19. https://geekymedics.com/erythema-nodosum/
  20. https://rarediseases.org/rare-diseases/panniculitis-idiopathic-nodular/
  21. https://www.osmosis.org/answers/panniculitis
  22. https://app.pulsenotes.com/medicine/dermatology/notes/erythema-nodosum
  23. https://pubmed.ncbi.nlm.nih.gov/8987051/
  24. https://dermnetnz.org/topics/erythema-nodosum
  25. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.837568/full
  26. https://emedicine.medscape.com/article/1081633-overview
  27. https://www.hopkinsmedicine.org/health/conditions-and-diseases/erythema-nodosum
  28. https://www.jaadinternational.org/article/S2666-3287%2824%2900042-7/fulltext
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC12149367/
  30. https://www.ncbi.nlm.nih.gov/books/NBK538517/
  31. https://www.cureus.com/articles/334712-a-scoping-literature-review-of-pancreatic-panniculitis
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC12536621/
  33. https://onlinelibrary.wiley.com/doi/10.1002/mus.21487
  34. https://emedicine.medscape.com/article/1082003-overview
  35. https://my.clevelandclinic.org/health/diseases/panniculitis
  36. https://www.dermatologyadvisor.com/home/decision-support-in-medicine/dermatology/erythema-nodosum-3/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC7571882/
  38. https://omim.org/entry/617099
  39. https://www.jaad.org/article/S0190-9622%2806%2903160-4/fulltext
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10043697/
  41. https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/MMR_II-PM_E.pdf
  42. https://www.odermatol.com/odermatology/12014/20.panniculitis-MartinezBragaG.pdf
  43. https://plasticsurgerykey.com/panniculitis-5/
  44. https://pubmed.ncbi.nlm.nih.gov/11464178/
  45. https://dermnetnz.org/topics/poststeroid-panniculitis-pathology
  46. https://medicaljournalssweden.se/actadv/article/download/16759/20625
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC9907651/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC5362841/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC5128879/
  50. https://www.jaad.org/article/S0190-9622(01)57690-2/fulltext
  51. https://www.pathologyoutlines.com/topic/skinnontumorlipodermatosclerosis.html
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC7263116/
  53. https://www.ncbi.nlm.nih.gov/books/NBK592380/
  54. https://pubmed.ncbi.nlm.nih.gov/18793986/
  55. https://www.pathologyoutlines.com/topic/skinnontumorcalciphylaxis.html
  56. https://emedicine.medscape.com/article/1081633-treatment
  57. https://www.mayoclinic.org/diseases-conditions/alpha-1-antitrypsin-deficiency/diagnosis-treatment/drc-20588792
  58. https://acrabstracts.org/abstract/cutaneous-panniculitis-in-rheumatology-a-descriptive-cohort-study-from-a-multidisciplinary-experience/
  59. https://www.medicalnewstoday.com/articles/320672
  60. https://dermnetnz.org/topics/nodular-panniculitis
  61. https://ard.bmj.com/content/76/Suppl_2/720.1
  62. https://my.clevelandclinic.org/health/diseases/24187-fat-necrosis
  63. https://emedicine.medscape.com/article/1008411-treatment
Add your contribution
Related Hubs
User Avatar
No comments yet.